Fabry Disease Treatment Market By Treatment Type (Enzyme Replacement Therapy (ERT), Chaperone Therapy, Substrate Reduction Therapy (SRT) and Supportive Care), By Route of Administration (Intravenous (IV), Oral and Subcutaneous), By End-user (Hospitals, Specialty Clinics, Home Healthcare and Long-term Care Facilities), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Published Date: Oct 2024 | Report ID: MI1229 | 215 Pages

Report Summary Table of Contents Segmentation FAQ Request Free Sample Report

Report Coverage:

By Treatment Type  

  • Enzyme Replacement Therapy (ERT)
  • Chaperone Therapy
  • Substrate Reduction Therapy (SRT)
  • Supportive Care

By Route of Administration

  • Intravenous (IV)
  • Oral
  • Subcutaneous

By End-user

  • Hospitals
  • Specialty Clinics
  • Home Healthcare
  • Long-term Care Facilities

By Region

North America

  • U.S.
  • Canada

Europe

  • U.K.
  • France
  • Germany
  • Italy
  • Spain
  • Rest of Europe

Asia Pacific

  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Singapore
  • Rest of Asia Pacific

Latin America

  • Brazil
  • Argentina
  • Mexico
  • Rest of Latin America

Middle East & Africa

  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

List of Companies:

  • Sanofi Genzyme
  • Amicus Therapeutics
  • Shire (Takeda)
  • Pfizer
  • Boehringer Ingelheim
  • Ultragenyx Pharmaceutical
  • Sobi (Swedish Orphan Biovitrum)
  • Zymeworks
  • Alder BioPharmaceuticals
  • Horizon Therapeutics
  • Protalix BioTherapeutics
  • Eidos Therapeutics
  • Avrobio
  • Cure Fabry Foundation
  • Novartis

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.

Request Bundle Pricing